Histogen - HSTO Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Histogen in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" HSTO shares.
View HSTO analyst ratings or view top-rated stocks.

1 brokerages have issued 12 month price objectives for Histogen's shares. Their HSTO share price forecasts range from $30.00 to $30.00. On average, they expect the company's share price to reach $30.00 in the next year. This suggests a possible upside of 2,155.6% from the stock's current price.
View analysts price targets for HSTO or view top-rated stocks among Wall Street analysts.

Histogen's stock was trading at $0.83 on January 1st, 2023. Since then, HSTO shares have increased by 60.2% and is now trading at $1.33.
View the best growth stocks for 2023 here.

Histogen saw a decline in short interest during the month of February. As of February 28th, there was short interest totaling 10,200 shares, a decline of 34.6% from the February 13th total of 15,600 shares. Based on an average trading volume of 65,800 shares, the short-interest ratio is currently 0.2 days. Approximately 0.2% of the shares of the company are sold short.
View Histogen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our HSTO earnings forecast.

Histogen Inc. (NASDAQ:HSTO) released its earnings results on Thursday, March, 9th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.14. Histogen had a negative net margin of 294.75% and a negative trailing twelve-month return on equity of 68.79%.

Histogen's stock reverse split on Friday, June 3rd 2022. The 1-20 reverse split was announced on Friday, June 3rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 3rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Histogen investors own include Carnival Co. & (CCL), Intel (INTC), Genius Brands International (GNUS), Gilead Sciences (GILD), Clovis Oncology (CLVS), B2Gold (BTG), BIOLASE (BIOL), (BBI.V) (BBI), Advanced Micro Devices (AMD) and Akers Biosciences (AKER).

Histogen trades on the NASDAQ under the ticker symbol "HSTO."

Histogen's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.

Shares of HSTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HSTO stock can currently be purchased for approximately $1.33.

Histogen (NASDAQ:HSTO) has a market capitalization of $5.68 million and generates $3.77 million in revenue each year. The company earns $-10,620,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis.

Histogen's mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The official website for the company is www.histogen.com. The company can be reached via phone at (858) 526-3100 or via email at aengbring@conatuspharma.com.